AR105223A1 - Compuestos químicos - Google Patents

Compuestos químicos

Info

Publication number
AR105223A1
AR105223A1 ARP160100159A ARP160100159A AR105223A1 AR 105223 A1 AR105223 A1 AR 105223A1 AR P160100159 A ARP160100159 A AR P160100159A AR P160100159 A ARP160100159 A AR P160100159A AR 105223 A1 AR105223 A1 AR 105223A1
Authority
AR
Argentina
Prior art keywords
nanoparticles
sugar
compositions
polymers
useful
Prior art date
Application number
ARP160100159A
Other languages
English (en)
Inventor
Oh Sejin
Borros Salvador
Original Assignee
Sagetis Biotech Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sagetis Biotech Sl filed Critical Sagetis Biotech Sl
Publication of AR105223A1 publication Critical patent/AR105223A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Manufacturing & Machinery (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)

Abstract

Nanopartículas que comprenden un poli(b-amino-éster) modificado en el extremo y un aditivo que es un azúcar o un derivado de azúcar, como ser un azúcar, un alcohol de azúcar o quitosano. Las nanopartículas pueden ser empleadas en cualquier campo en el que los polímeros resulten de utilidad, incluso en el campo de la medicina, en particular para la administración de fármacos. Los polímeros resultan útiles para la administración de un polinucleótido como ser ADN, ARN o siARN, una molécula pequeña cuna proteína. Composiciones que comprenden dichas nanoparticulas y un agente activo, métodos para la preparación de dichas nanopartículas, dichas nanopartículas y composiciones para ser empleadas en medicina, y métodos in vitro que utilizan dichas nanopartículas y composiciones.
ARP160100159A 2015-01-21 2016-01-21 Compuestos químicos AR105223A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1501025.9A GB201501025D0 (en) 2015-01-21 2015-01-21 Chemical compounds

Publications (1)

Publication Number Publication Date
AR105223A1 true AR105223A1 (es) 2017-09-20

Family

ID=52630915

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160100159A AR105223A1 (es) 2015-01-21 2016-01-21 Compuestos químicos

Country Status (6)

Country Link
US (1) US20180000968A1 (es)
EP (1) EP3247338A1 (es)
AR (1) AR105223A1 (es)
GB (1) GB201501025D0 (es)
TW (1) TW201632206A (es)
WO (1) WO2016116887A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019213290A1 (en) 2018-01-17 2020-08-06 Ixaka France SAS Polymer-encapsulated viral vectors for genetic therapy
EP3969166A1 (fr) 2019-05-16 2022-03-23 Gem Innov Procede de preparation de microcapsules biodegradables et microcapsules ainsi obtenues
CA3151983A1 (en) 2019-09-21 2021-03-25 Ozgul TEZGEL Dmso-free synthesis of oligopeptide-modified poly(beta-amino ester)s and their use in nanoparticle delivery systems
CA3158561A1 (en) 2019-11-15 2021-05-20 Frederic Mourlane Polymer-encapsulated viral vectors for in vivo genetic therapy
CN115803438A (zh) 2020-05-19 2023-03-14 艾夏卡法国有限公司 用于cd3+细胞体外和体内表达基因治疗产物的启动子序列
CN111944845B (zh) * 2020-07-30 2022-06-07 珠海舒桐医疗科技有限公司 靶向敲除人乳头瘤病毒或疱疹病毒关键基因的复合纳米粒的制备
EP4166594A1 (en) * 2021-10-14 2023-04-19 Institut Químic de Sarrià CETS Fundació Privada Zwitterionic functionalized poly(beta-aminoester) polymers and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8257740B1 (en) * 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
WO2008109806A2 (en) * 2007-03-08 2008-09-12 Massachusetts Institute Of Technology Electrostatic coating of particles for drug delivery
GB201304245D0 (en) * 2013-03-08 2013-04-24 Inst Quimic De Sarria Chemical compounds
WO2016019126A1 (en) * 2014-07-30 2016-02-04 The Research Foundation For The State University Of New York System and method for delivering genetic material or protein to cells

Also Published As

Publication number Publication date
GB201501025D0 (en) 2015-03-04
TW201632206A (zh) 2016-09-16
EP3247338A1 (en) 2017-11-29
US20180000968A1 (en) 2018-01-04
WO2016116887A1 (en) 2016-07-28

Similar Documents

Publication Publication Date Title
AR105223A1 (es) Compuestos químicos
AR095081A1 (es) Compuestos químicos
MX2021001118A (es) Composiciones que comprenden fibras obtenidas electrohidrodinamicamente para la administracion de dosificaciones especificas de una sustancia activa a piel o mucosa.
CL2018000706A1 (es) Derivados de pirazolopirimidina como inhibidores btk para el tratamiento del cancer.
CL2018000705A1 (es) Método de cristalización y biodisponibilidad
MX2017004306A (es) Formulaciones de polisacáridos y ácido nucleico que contienen agentes de reducción de viscosidad.
MX2015012433A (es) Matriz de microestructura para suministro de agentes activos.
ECSP15004752A (es) Formulaciones de etanercept que muestran una marcada reducción de la cantidad de partículas subvisibles
CR20150604A (es) Proceso para la preparación de eritrocitos cargados con una o más sustancias de interés farmacéutico y eritrocitos así obtenidos
CR20140475A (es) Agentes terapéuticos para administración subcutánea optimizados
EP4360621A3 (en) Formulations of bendamustine
CY1120488T1 (el) Υγρη φαρμακευτικη συνθεση
ECSP17085443A (es) Formulación sólida oral que contiene irinotecán y método de preparación de la misma
MX2016012319A (es) Formulaciones antihelminticas veterinarias estables.
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CL2012003209A1 (es) Metodo de sintesis de nanoparticulas de acido poli (lactico-glicolico) (plga) con pentoxifilina; composicion farmaceutica que comprende nanoparticulas de plga con pentoxifilina; y uso de las nanoparticulas de plga cargada con pentoxifilina en el tratamiento del alivio y prevencion del dolor cronico.
MX2021002633A (es) Dispersiones solidas de bendamustina e infusion continua.
CO2018011420A2 (es) Formulaciones líquidas de fosfaplatino
BR112018010400A8 (pt) ?formulação de uma proteína, e, método para preparação de uma formulação de uma proteína?
EP3310786A4 (en) Drug delivery and imaging chemical conjugate, formulations and methods of use thereof
BR112017012975A2 (pt) formulações injetáveis de paracetamol
AR110595A1 (es) Sistema para la entrega de polímeros líquidos para la administración prolongada de fármacos
CL2015003702A1 (es) Formulación farmacéutica en forma de micropartículas estériles, que comprenden como agente activo rhein, y copolímeros del ácido láctico y glicólico (plga). proceso de elaboración y uso en pacientes que presentan patologías articulares.
CO2018002575A2 (es) Composición de estabilidad mejorada de etanercept

Legal Events

Date Code Title Description
FB Suspension of granting procedure